Results 41 to 50 of about 21,698 (162)

Vegetating Lupus Vulgaris in a Child

open access: yes
JEADV Clinical Practice, EarlyView.
Viktor Pushkarenko   +2 more
wiley   +1 more source

Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT Culture‐based monitoring of bacterial load is slow and susceptible to missing data, contributing to the length and cost of TB clinical trials. Non‐culture‐based alternatives, like the Tuberculosis Molecular Load Bacterial Assay (TB‐MBLA), could represent a solution.
Mairi C. W. McClean   +15 more
wiley   +1 more source

A Painful Purpuric Rash in a Febrile Smoker

open access: yes
JEADV Clinical Practice, EarlyView.
Eugerta Dilka   +3 more
wiley   +1 more source

Primary Tracheal Rosai‐Dorfman Disease Coexisting With Active Pulmonary Tuberculosis

open access: yesRespirology Case Reports, Volume 14, Issue 8, August 2026.
We report a rare case of primary tracheal Rosai‐Dorfman disease (RDD) with active pulmonary tuberculosis. Bronchoscopic resection immediately relieved > 90% airway obstruction, and anti‐tuberculosis therapy was given, resulting in no recurrence at one‐year follow‐up. ABSTRACT Rosai‐Dorfman disease (RDD) rarely involves the trachea, and active pulmonary
Shijie Yang   +4 more
wiley   +1 more source

LEVEL OF URIC ACID IN BLOOD SERUM OF NEW PULMONARY TUBERCULOSIS PATIENTS WITH MULTIPLE DRUG RESISTANCE

open access: yesТуберкулез и болезни лёгких, 2017
The level of uric acid in blood serum was investigated in 134 new patients suffering from multiple drug resistant pulmonary tuberculosis (78 men and 56 women). The tests were performed by admission to hospital and then repeated in 1, 2, 3, 4, 5, 6, 7 and
R. Yu. Аbdullaev   +3 more
doaj   +1 more source

Applying a Pharmacometrics‐Enabled Machine Learning Analysis to Predict 2‐Month Culture Conversion Using Phase 2a Data in a Tuberculosis Clinical Trial

open access: yesClinical and Translational Science, Volume 19, Issue 8, August 2026.
A workflow for appying pharmacometrics‐enable machine learning analysis to predict 2‐month culture conversion using phase 2a data. ABSTRACT Phase 2a trials in tuberculosis patients traditionally assess early bactericidal activity over two weeks, often using the time‐to‐positivity biomarker, followed by a phase 2b study typically lasting 8‐week with ...
Huifang You, Ulrika S. H. Simonsson
wiley   +1 more source

A 34-Year-Old Obese Woman with Rash, Finger Swelling and Fever

open access: yesInternational Journal of Infectious Diseases, 2017
Disseminated tuberculosis first presenting as cutaneous lesion is uncommon and difficult to diagnose on account of its divers clinical forms. We present a 34-year-old obese woman with rash, finger swelling and fever. The patient was firstly manifested by
Na Huo   +6 more
doaj   +1 more source

Should TNF inhibitors be avoided in psoriasis patients with latent tuberculosis?

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Fabià Torres‐Betato, Lluís Puig
wiley   +1 more source

Pellagra in Contemporary Clinical Practice (2000–2023): A Systematic Review

open access: yesInternational Journal of Dermatology, Volume 65, Issue 8, Page 1590-1599, August 2026.
This systematic review (2000–2023) of 1212 cases highlights pellagra's evolving etiology. While primary dietary deficiency (85%) persists in humanitarian crises, secondary forms from alcohol misuse (9.6%), isoniazid (14.3% of drug‐related cases), and malabsorption are rising.
Noureddine Litaiem   +2 more
wiley   +1 more source

Biphasic Medium Using Nicotinamide for Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis

open access: yesAntibiotics
Reliable drug susceptibility testing of pyrazinamide (PZA) is technically difficult, since PZA activity is pH sensitive. The aim of this study was to evaluate a biphasic medium assay (BMA) for the reliable detection of PZA resistance in Mycobacterium ...
Waraporn Thuansuwan   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy